New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 11, 2014
16:31 EDTACTActavis confirms generic Diclegis patent challenge
Actavis confirmed that it has filed an Abbreviated New Drug Application, or ANDA, with the FDA seeking approval to market Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-release tablets. Actavis' ANDA product is a generic version of Duchesnay Inc.'s Diclegis, which is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. Duchesnay Inc. and Duchesnay USA Inc., filed suit against Actavis on July 10, in the U.S. district court for the district of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of certain U.S. Patents. Actavis believes it may be a "first applicant" to file an ANDA for the generic version of Diclegis.
News For ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ACT

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use